Biosimilar Antibodies

Lodelcizumab is a monoclonal antibody that specifically targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is utilized in research settings to investigate the biological mechanisms and potential therapeutic interventions for hypercholesterolemia. Lodelcizumab binds to PCSK9, inhibiting its function, which is crucial in the regulation of cholesterol levels in the bloodstream. This makes it a valuable tool for studies focused on lipid metabolism and cardiovascular disease.

Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody, engineered with high binding affinity and produced in CHO cells. This antibody effectively blocks the interaction between the MERS-CoV spike protein and the DPP4 receptor, thereby inhibiting the virus's entry into host cells. It is an essential tool for research focused on the molecular mechanisms of MERS-CoV infection and potential therapeutic interventions.

Tanezumab (RN-624) is a humanized monoclonal antibody that exhibits high affinity and specificity for nerve growth factor (NGF). By effectively blocking the interaction of NGF with its receptors, p75 and TrkA, Tanezumab modulates pain signaling pathways in the peripheral nervous system. This antibody is utilized extensively in research focused on both acute and chronic pain conditions, including osteoarthritis, knee pain, neuralgia, and post-herpetic neuralgia, providing a valuable tool for the study of pain mechanisms and therapeutic interventions.

Anivovetmab (KIND-030) is a monoclonal antibody of the IgG2 subtype, specifically targeting the VP2 protein, a major capsid protein of the canine parvovirus. This antibody is designed for the investigation of canine parvovirus infections, providing a critical tool for research into the pathogenesis and immune response to this virus. Anivovetmab is instrumental in advancing our understanding of viral mechanisms and potential therapeutic interventions for canine parvovirus.

The Anti-GAD65 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the GAD65 enzyme. This antibody features a human IgG1 heavy chain and a human lambda light chain, with a predicted molecular weight of 146.48 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is essential for research focused on the enzymatic function and regulation of GAD65, particularly in studies related to its role in neurological and autoimmune disorders.

Flotetuzumab (MGD006; S80880) is a bispecific dual-affinity retargeting antibody (DART) that targets CD123 and CD3, designed for the treatment of acute myeloid leukemia (AML). This investigational molecule facilitates T-cell activation by concurrently engaging CD123 on target cells and CD3 on effector T cells. This interaction promotes T-cell-mediated cytotoxicity against the target cells. Efficacy studies, including those using a mouse model with patient-derived xenografts (PDX), have demonstrated flotetuzumab's potential to inhibit the progression of AML.

Cudarolimab (IBI101) is a fully human monoclonal antibody that targets OX40 (CD134), a costimulatory molecule predominantly expressed on activated immune cells. By inhibiting the interaction between OX40 and its ligand OX40L, Cudarolimab effectively modulates immune responses. This antibody demonstrates significant antitumor activity, making it particularly useful in cancer research studies.

CC-90002 is a humanized monoclonal antibody targeting CD47 with high specificity and subnanomolar affinity, evidenced by its dissociation constant (Kd). This antibody is designed for advanced studies in both hematologic malignancies and solid tumors, providing a critical tool for research in cancer therapy mechanisms and potential therapeutic interventions.

Pegrizeprument is a chimeric antibody of the Fab'-G1 -κ type, specifically targeting the CD28 receptor. This antibody is designed for high specificity and affinity in binding to the CD28 molecule, a critical co-stimulatory receptor involved in T-cell activation and survival. Pegrizeprument's unique structure and targeting capability make it an essential tool for research in immunology, particularly in studies related to T-cell function and immune response regulation.

Detumomab is a mouse-derived monoclonal antibody specifically designed to target human B-cell lymphoma. This antibody is particularly useful in the study of various cancers, including non-Hodgkin's lymphoma (NHL), providing essential insights into disease mechanisms and potential therapeutic targets.

Cizutamig is a dimeric humanized antibody that specifically targets TNFRSF17. It is constructed with a light chain kappa and heavy gamma 1 chain variable region, featuring a VH-G1 (CH1-h) configuration. This antibody is designed for high specificity and affinity in applications involving TNFRSF17 interaction studies.

Falbikitug is a humanized IgG1-kappa monoclonal antibody targeting leukemia inhibitory factor (LIF). Classified as an antineoplastic agent, Falbikitug is designed for therapeutic applications in oncology, specifically targeting and neutralizing LIF to inhibit tumor growth and progression. This antibody may be utilized in research studies to explore the role of LIF in cancer biology and to assess its potential as a therapeutic target in various malignancies.

Bimagrumab is a human monoclonal antibody designed to inhibit the activin type II receptor (ActRII), demonstrating high affinity with dissociation constants (KDs) of 1.7 pM for ActRIIB and 434 pM for ActRIIA. This specificity suggests its utility in investigating the mechanisms underlying pathological muscle loss and weakness. Bimagrumab serves as an essential tool for research focused on muscle degenerative diseases by targeting and modulating the signaling pathways involved in muscle growth and repair.

Afelimomab (MAK 195F) is a monoclonal antibody fragment, specifically an F(ab')2 fragment, targeting tumor necrosis factor (TNF). This antibody fragment is utilized primarily in the study of sepsis, offering a valuable tool for researchers investigating the pathophysiology and potential therapeutic interventions for this condition.

Tefibazumab is a humanized IgG1κ monoclonal antibody specifically designed to target and bind to clumping factor A, a surface-expressed adhesion protein. This antibody is utilized primarily in the study of serious infections caused by Staphylococcus aureus, offering a valuable tool for research in microbial pathogenesis and immune response mechanisms.

GEN-1053 (BNT-313) is a fully human monoclonal antibody of the IgG1 subclass, specifically targeting CD27. Upon binding to its antigen, GEN-1053 facilitates the formation of a hexameric structure. For experimental control purposes, Human IgG1 lambda1 serves as the appropriate isotype control for GEN-1053. This antibody is crucial for studies focusing on the modulation of the CD27 signaling pathway, which is significant in immune regulation and has implications in therapeutic interventions for immune disorders and cancers.

Tebentafusp (IMCgp100) is a bispecific fusion protein designed to specifically target the gp100 peptide-HLA-A*02:01 complex, an antigen commonly associated with melanoma. This innovative therapeutic agent employs a dual-action mechanism: it features a high-affinity T-cell receptor (TCR) binding domain that recognizes and binds to gp100-expressing tumor cells, coupled with an anti-CD3 T-cell engaging domain that recruits and activates T cells. Upon engagement, Tebentafusp mediates the production of inflammatory cytokines and cytolytic proteins, culminating in the direct lysis of tumor cells. This targeted approach not only enhances the specificity of T-cell mediated tumor cell killing but also minimizes off-target effects, making it a promising candidate for melanoma therapy.

Narnatumab (IMC-RON8) is a human monoclonal antibody designed to neutralize RON receptor activity by inhibiting its interaction with the macrophage-stimulating protein (MSP). This antibody demonstrates a high affinity for the RON receptor with a dissociation constant (Kd) of 32 pM. Narnatumab is primarily utilized in cancer research, where it serves as a critical tool for studying the role of the RON receptor in tumor progression and metastasis.

Firivumab (CT-P22; CT120) is a human IgG1 monoclonal antibody targeting influenza A virus hemagglutinin (Anti-IAV HA). This antibody demonstrates a broad neutralizing capacity against multiple subtypes including H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2, and H12N7. In vivo studies have confirmed Firivumab's protective efficacy against the H1N1 virus in murine models, highlighting its potential for therapeutic applications in influenza A virus infections.

Ulocuplumab, also known as BMS-936564 or MDX1338, is a fully human IgG4 monoclonal antibody targeting CXCR4. This antibody plays a critical role in modulating tumor microenvironment interactions by inducing apoptosis and inhibiting CXCL12-mediated activation and migration of CXCR4 in chronic lymphocytic leukemia (CLL) cells. Demonstrating significant antitumor efficacy, Ulocuplumab has shown activity against established tumors in various xenograft models, including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma. This antibody is pivotal for research focused on the molecular pathways of cancer cell migration and survival, offering potential therapeutic insights into multiple hematologic malignancies.

Roconkibart is a human IgG4 κ monoclonal antibody targeting IL-17A. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for the specific detection and neutralization of IL-17A, a key cytokine involved in inflammatory processes and autoimmune disorders.

IMA-026 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-13 (IL-13). This antibody is constructed with a human IgG1 heavy chain and a human kappa light chain, and possesses a predicted molecular weight of 146.88 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Galiximab (IDEC 114) is a primatized monoclonal antibody of the immunoglobulin G1 (IgG1) lambda class, specifically targeting the CD80 antigen to inhibit the CD80-CD28 interaction. This antibody features variable regions derived from cynomolgus monkeys and human constant regions. Galiximab is commonly utilized in the study of B-cell lymphoma, providing a valuable tool for investigating the role of CD80 in immune modulation and cancer biology.

Inezetamab is a bispecific IgG1 monoclonal antibody that targets both CD40 and mesothelin (MSLN). This dual specificity enables it to engage multiple pathways involved in immune modulation and tumor cell targeting, making it a valuable tool for research in cancer immunotherapy and related fields.

Delpacibart is a humanized IgG1κ monoclonal antibody specifically designed to target the transferrin receptor (TFRC). TFRC is a critical membrane protein that plays a pivotal role in regulating intracellular iron transport. This antibody is instrumental in studies focusing on iron metabolism and related cellular processes.

The Anti-TPSAB1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the TPSAB1 protein, which is critical in various biological processes. This antibody is composed of a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG4 kappa, Isotype Control is recommended.

Brivekimig is a chimeric antibody composed of five variable heavy (VH) domains, specifically designed to target TNFSF4, TNFSF2, and albumin (ALB). This unique configuration enhances its specificity and binding affinity, making it an ideal tool for research into the signaling pathways and biological effects mediated by these targets. Brivekimig is suitable for use in various experimental contexts to elucidate the roles of TNFSF4 and TNFSF2 in immune regulation and inflammatory processes.

Suvonstobart is a monoclonal antibody that specifically targets human CD24, a signal transducer integral to various immune cell signaling pathways. By binding to CD24, Suvonstobart activates these pathways, demonstrating both immunostimulatory and antitumor properties. This antibody is utilized primarily in research focused on cancer immunotherapy and the modulation of immune responses.

Lifastuzumab is a humanized monoclonal antibody of the IgG1 subtype, targeting the sodium-dependent phosphate transport protein 2b (NaPi2b). This antibody can be conjugated to monomethyl auristatin E (MMAE) via an ADC linker, creating the antibody-drug conjugate lifastuzumab vedotin (DNIB0600A). The resulting conjugate exhibits potent anticancer activity, making it a valuable tool for targeted cancer therapy research.

Budigalimab (ABBV 181; PR 1648817) is a humanized recombinant IgG1 monoclonal antibody specifically designed to target the programmed cell death 1 (PD-1) receptor. This antibody features a modified Fc region with a mutation that diminishes Fc receptor interactions and effector function inhibition. By effectively blocking the interaction between PD-1 and its ligand PD-L1, Budigalimab exhibits potent anti-tumor activity. It is primarily utilized in research focused on various solid tumors, providing a valuable tool for oncology studies.

Telazorlimab (GBR-830) is a humanized monoclonal antibody designed to target the OX40 costimulatory receptor, which is expressed on activated T cells. This antibody is utilized primarily in the study of autoimmune diseases, offering a valuable tool for researchers exploring the modulation of T cell responses in various immunological conditions.

Vunakizumab is a recombinant human IgGκ monoclonal antibody specifically designed to target and neutralize interleukin-17A (IL-17A). By binding to IL-17A, Vunakizumab effectively prevents its interaction with the IL-17 receptor, thereby inhibiting the pro-inflammatory pathways associated with this cytokine. This antibody is particularly useful in research focused on autoimmune disorders, including psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis, where IL-17A plays a key role in disease pathogenesis.

Olinvacimab (TTAC-0001) is a fully human monoclonal antibody targeting VEGFR2, exhibiting potent antiangiogenic properties. This antibody binds specifically to the kinase insert domain receptor (KDR), a known alias for VEGFR2, with a high affinity characterized by a dissociation constant (Kd) of 0.23 nM. By inhibiting the vascular endothelial growth factor (VEGF) pathway, Olinvacimab effectively disrupts tumor angiogenesis. It is primarily utilized in research focused on investigating therapeutic approaches for recurrent glioblastoma and breast cancer.

Nebokitug is a human monoclonal antibody of the IgG1κ isotype designed to specifically target CCL24. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

VLST-002 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CCL5/RANTES. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

DCBY02 is a pioneering humanized IgG1 monoclonal antibody specifically developed to target CD93. This antibody is engineered to normalize tumor vasculature, thereby enhancing the infiltration of immune cells into the tumor microenvironment. Its mechanism promotes the efficacy of concurrent cancer immunotherapies, making it a valuable tool for advancing oncological research and therapeutic development.

The Anti-DDR1/CD167a Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target DDR1/CD167a, a receptor tyrosine kinase implicated in the regulation of cell growth and differentiation. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, with an approximate molecular weight of 150 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This product is ideal for use in research applications focusing on cellular signaling, cancer biology, and developmental processes.

Rinucumab (REGN 2176) is a monoclonal antibody designed to inhibit platelet-derived growth factor (PDGF), making it a valuable tool for research into neovascular age-related macular degeneration. This antibody specifically targets PDGF pathways, which are implicated in the pathological angiogenesis associated with this condition. Rinucumab (REGN 2176) is utilized primarily in studies aimed at understanding and potentially mitigating the progression of neovascular age-related macular degeneration.

Xeligekimab (GR 1501) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin 17A (IL-17A), a key cytokine involved in the induction and maintenance of pro-inflammatory responses. By binding to IL-17A, Xeligekimab effectively inhibits the cytokine's interaction with its receptor, thereby disrupting the pro-inflammatory cascade. This antibody is utilized in research focused on inflammatory diseases to understand the role of IL-17A in disease pathology and to evaluate potential therapeutic interventions.

Marstacimab (PF-06741086) is a monoclonal antibody targeting the tissue factor pathway inhibitor (TFPI). This antibody is utilized in the investigation of hemophilia, providing a valuable tool for exploring the regulation of coagulation pathways and potential therapeutic interventions.

Enoticumab (REGN421, SAR153192) is a monoclonal antibody of the IgG1κ subtype designed to specifically target human Delta-like ligand 4 (DLL4). DLL4 is an integral component of the Notch signaling pathway, which is known to influence a variety of cellular processes including the regulation of fatty acid uptake via non-transcriptional modulation of macropinocytosis-dependent mechanisms. This antibody has demonstrated significant efficacy in preclinical studies, particularly in models of ovarian cancer. Administration of Enoticumab at a dosage of 2.5 mg/kg once weekly led to tumor growth inhibition rates of 86% in subcutaneous TOV-112D and 83% in intraperitoneal A2780 human tumor xenograft models. These findings underscore its potential utility in therapeutic applications targeting DLL4-mediated pathways.

The Anti-Histone H3 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Histone H3. It is composed of a human IgG1 heavy chain and a human kappa light chain, and has a predicted molecular weight of 150 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for use in various biochemical assays where Histone H3 is a focus of study, providing essential insights into chromatin structure and function.

Casdozokitug (SRF-388) is a monoclonal antibody of the IgG1κ subclass that specifically targets interleukin-27 (IL-27). This antibody has been developed for its potential application in modulating immune responses, given IL-27's role in inflammatory processes. Casdozokitug is suitable for use in various immunological assays to study IL-27's biological functions and its implications in immune regulation and disease pathogenesis.

Pacmilimab (CX-072) is a potent inhibitor of programmed death-ligand 1 (PD-L1), exhibiting significant antitumor activity. This monoclonal antibody selectively binds to PD-L1, disrupting its interaction with PD-1 receptors on T cells, thereby enhancing the immune system's ability to attack tumor cells. Pacmilimab is primarily utilized in research focused on the modulation of immune checkpoints in oncology.

Umizortamig is a monoclonal antibody engineered to target CD3E, EGFR, TNFRSF9, PD-L1, and CD3G. This multi-specific antibody is designed for the simultaneous modulation of key immune checkpoints and signaling pathways, potentially enhancing therapeutic efficacy in oncology and immunotherapy applications. Umizortamig's ability to bind multiple targets allows for a coordinated approach in the regulation of immune responses, making it a valuable tool for research in cancer biology and immune regulation.

LIV-1205 (CBA-1205) is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Delta-like 1 homolog (DLK1). This antibody is composed of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, and exhibits a molecular weight of approximately 150 kDa. For experimental control purposes, the appropriate isotype control is designated as Human IgG1 kappa, Isotype Control.

Bedinvetmab (ZTS-00508841) is a canine-specific monoclonal antibody designed to target nerve growth factor (NGF). By inhibiting the interaction of NGF with its receptors, tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR), Bedinvetmab effectively modulates pain signaling pathways. This antibody is particularly useful for research into the management of osteoarthritis pain in canine models, providing a valuable tool for understanding and potentially mitigating pain mechanisms in dogs.